Silo Pharma Announces Data On SPC-15 For PTSD And Prepares To File Pre-Investigational New Drug Application With FDA
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma, Inc. (NASDAQ:SILO) has announced positive pre-clinical data for SPC-15, a targeted intranasal prophylactic for the treatment and prevention of anxiety, PTSD, and other stress-related disorders. The company is working with Kymanox to prepare a pre-Investigational New Drug (IND) package and meeting request with the FDA, with submission targeted for Q1 2024. Kymanox will provide regulatory affairs support, including the development of a clinical pharmacology and biopharmaceutics strategy and program.
September 20, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's announcement of positive pre-clinical data for SPC-15 and its preparation for a pre-IND submission to the FDA could potentially boost investor confidence in the company's research and development capabilities.
Positive pre-clinical data is a significant milestone in drug development, indicating that the drug has potential therapeutic benefits. This, coupled with the company's preparation for a pre-IND submission to the FDA, signals progress in the drug's development pathway, which could positively impact the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100